Stocks Health care NPCE
NASDAQ · Health careNeuroPace Inc (NPCE)
NeuroPace Inc brought in $102.9M of revenue over the twelve months to June 30, 2026, up 21.6% from a year earlier. It posted a net loss of $19.1M. In fiscal 2025 capital spending exceeded operating cash flow by $11.3M. At June 30, 2026 it held $12.5M in cash against $59M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about NeuroPace Inc
- Net worth
- NeuroPace Inc has a market value (market cap) of $435.6M at the latest share price, and shareholders' equity of $11.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $100M (+25.1% year on year), with a net loss of $21.5M. Over the 12 months to June 30, 2026: revenue $102.9M, net loss $19.1M.
- Cash flow
- In fiscal 2025 operations used $11M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- NeuroPace Inc's next report was expected around November 3, 2026 and is not on file with the SEC yet.
What NeuroPace Inc does
NeuroPace Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker NPCE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $100M | -$21.5M | -$0.66 | -$11.3M |
| 2024 | $79.9M | -$27.1M | -$0.93 | -$18.3M |
| 2023 | $65.4M | -$33M | -$1.27 | -$19.9M |
| 2022 | $45.5M | -$47.1M | -$1.91 | -$37.5M |
| 2021 | $45.2M | -$36.1M | -$2.17 | -$25M |
| 2021 | $41.1M | -$24.3M | -$117.85 | -$21.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NPCE ranks in Health care
Latest SEC filings
What NeuroPace Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 4, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 17% to $22.8M versus the same quarter last year; diluted EPS -$0.18 versus -$0.26.
- August 11, 2026
- July 28, 2026
- June 8, 2026
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 2% to $22.1M versus the same quarter last year; diluted EPS -$0.20 versus -$0.21.
- May 12, 2026
Insider trades
What the people running NeuroPace Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 24, 2026 | Morrell MarthaCHIEF MEDICAL OFFICER | Shares withheld for tax | 335 | $4.7K |
| September 20, 2026 | Williams Patrick F.Chief Financial Officer | Shares withheld for tax | 1,162 | $16.6K |
| September 3, 2026 | Becker JoelCHIEF EXECUTIVE OFFICER, Director | Shares withheld for tax | 1,310 | $19.3K |
| August 27, 2026 | Becker JoelCHIEF EXECUTIVE OFFICER, Director | Shares withheld for tax | 1,126 | $15.9K |
| August 27, 2026 | Morrell MarthaCHIEF MEDICAL OFFICER | Shares withheld for tax | 358 | $5.1K |
| June 24, 2026 | Morrell MarthaCHIEF MEDICAL OFFICER | Shares withheld for tax | 335 | $5.4K |
| June 19, 2026 | Fischer Frank MDirector | Received as pay | 1,467 | $22.9K |
| June 19, 2026 | Geiger UriDirector | Received as pay | 789 | $12.3K |
Who owns NPCE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Mathew P. Arens13G, passive with 1 related filers | 12.25% | September 4, 2026 |
| Polar Capital Holdings Plc13G, passive with 1 related filers | 9.13% | May 15, 2025 |
| Guy Levy13G, passive with 8 related filers | 8.9% | November 7, 2025 |
| Morgan Stanley13G, passive with 1 related filers | 8.3% | February 4, 2025 |
| Soleus Capital Management, L.P.13G, passive with 8 related filers | 7% | August 5, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 113 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Polar Capital Holdings Plc | 3,298,104 | 0 |
| Soleus Capital Management, L.P. | 2,911,122 | -21,085 |
| First Light Asset Management, LLC | 2,861,167 | +401,201 |
| Morgan Stanley | 2,654,391 | +87,552 |
| BlackRock, Inc. | 2,477,603 | +131,270 |
| Orbimed Advisors LLC | 1,505,125 | -591,402 |
| Driehaus Capital Management LLC | 1,447,391 | -4,220 |
| Vanguard Capital Management LLC | 1,227,072 | +103,361 |
| Deutsche Bank AG\ | 938,919 | +6,829 |
| Armistice Capital, LLC | 692,000 | 0 |
| Geode Capital Management, LLC | 666,300 | +48,181 |
| Fmr LLC | 554,771 | +1,242 |
| State Street Corp | 550,132 | +52,586 |
| Silvercrest Asset Management Group LLC | 344,124 | -15,941 |
| Northern Trust Corp | 260,025 | +20,185 |
| Qube Research & Technologies Ltd | 221,237 | +35,048 |
| Vanguard Portfolio Management LLC | 220,371 | +32,942 |
| Palumbo Wealth Management LLC | 209,199 | -1,270 |
| Essex Investment Management Co LLC | 208,703 | -9,035 |
| Algert Global LLC | 184,774 | +5,218 |
Insiders
10 insiders reported holding 921,399 shares in total, about $11.7M at the last price.
| Holder | Shares |
|---|---|
| Fischer Frank MDirector | 599,534 |
| Becker JoelCHIEF EXECUTIVE OFFICER, Director | 138,000 |
| Williams Patrick F.Chief Financial Officer | 67,508 |
| Morrell MarthaCHIEF MEDICAL OFFICER | 51,357 |
| Kumar RakhiDirector | 23,039 |
| Geiger UriDirector | 18,537 |
| Lacob JosephDirector | 14,754 |
| Andrade LisaDirector | 2,890 |
| Ryan ReneeDirector | 2,890 |
| Huennekens R ScottDirector | 2,890 |
Questions about NPCE
What does NeuroPace Inc do?
NeuroPace Inc is a company in the Health care sector, listed on NASDAQ as NPCE. Its shares trade on NASDAQ under the ticker NPCE.
What is NeuroPace Inc's net worth?
NeuroPace Inc has a market value (market cap) of $435.6M at the latest share price, and shareholders' equity of $11.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is NeuroPace Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $19.1M on revenue of $102.9M.
How much revenue does NeuroPace Inc make?
Over the twelve months to June 30, 2026 NeuroPace Inc reported revenue of $102.9M. That is 21.6% more than a year earlier.
When did NeuroPace Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 25, 2026.
When is NeuroPace Inc's next earnings report?
NeuroPace Inc's next report was expected around November 3, 2026 and is not on file with the SEC yet.
Similar companies
Compare NPCE with
Follow NPCE
Get an email when NeuroPace Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values NeuroPace Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.